RO5186582 - first doses in humans and brain uptake by PET (ver 1)

• Research type

  Research Study

• Full title

  A two-part single-center, randomized, double-blind, single ascending dose, placebo-controlled, parallel study to investigate safety, tolerability, pharmacokinetics, and pharmacodynamics of RO5186582 in healthy young male subjects and to assess the occupancy of brain GABAA a5 subunit containing receptors following single oral administration in healthy young male subjects in an open label non-randomized, parallel group design. (HMR code 09-015)

• IRAS ID

  36585

• Sponsor organisation

  Roche Products Limited

• Eudract number

  2009-016097-33

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  N/A

• REC name

  London - Brent Research Ethics Committee

• REC reference

  09/H0717/79

• Date of REC Opinion

  8 Dec 2009

• REC opinion

  Favourable Opinion